Operation Warp Speed: implications for global vaccine security

Kim, J. H.
Hotez, P.
Bottazzi, M. E.
Lall, B.
Sheahan, T.
Shoham, S.
Yadav, P.
Batista, C.
Ergonul, O.
Gürsel, Mayda
Figueroa, J. P.
Gilbert, S.
Larson, H.
Wilder-Smith, A.
Hassanain, M.
Kang, G.
Naniche, D.
Strub-Wourgaft, N.
Several global efforts are underway to develop COVID-19 vaccines, and interim analyses from phase 3 clinical testing have been announced by nine organisations: Pfizer, the Gamaleya Research Institute of Epidemiology and Microbiology, Moderna, AstraZeneca, Sinopharm Group, Sinovac Biotech, Johnson & Johnson, Novavax, and CanSino Biologics. The US programme known as Operation Warp Speed provided US$18 billion in funding for development of vaccines that were intended for US populations. Depending on safety and efficacy, vaccines can become available through mechanisms for emergency use, expanded access with informed consent, or full licensure. An important question is: how will these Operation Warp Speed vaccines be used for COVID-19 prevention in global health settings? We address some key questions that arise in the transition from US to global vaccine prevention efforts and from ethical and logistical issues to those that are relevant to global vaccine security, justice, equity, and diplomacy.


Preparation and labeling of surface-modified magnetoferritin protein cages with a rhenium(I) carbonyl complex for magnetically targeted radiotherapy
Aslan, Tugba Nur; Asik, Elif; Volkan, Mürvet (Royal Society of Chemistry (RSC), 2016-01-01)
New rhenium radiolabeled compounds are of general interest due to their nuclear characteristics which allow radiotherapy and in situ monitoring of tumor uptake. Biocompatible magnetic nanoparticles capable of transporting radionuclides, providing MRI contrast agent properties for imaging and a therapeutic effect in the target tissue simultaneously, are highly desirable. Herein we describe the preparation of magnetoferritin samples, and their labeling with rhenium in the form of the low oxidation state rheni...
Synthesis of novel 6-substituted amino-9-(beta-D-ribofuranosyl)purine analogs and their bioactivities on human epithelial cancer cells
TUNÇBİLEK, MERAL; Kucukdumlu, Asligul; Guven, Ebru Bilget; Altiparmak, Duygu; Atalay, Rengül (2018-02-01)
New nucleoside derivatives with nitrogen substitution at the C-6 position were prepared and screened initially for their in vitro anticancer bioactivity against human epithelial cancer cells (liver Huh7, colon HCT116, breast MCF7) by the NCI-sulforhodamine B assay. N-6-(4-trifluoromethylphenyl) piperazine analog (27) exhibited promising cytotoxic activity. The compound 27 was more cytotoxic (IC50 = 1-4 mu M) than 5-FU, fludarabine on Huh7, HCT116 and MCF7 cell lines. The most potent nucleosides (11, 13, 16,...
Evaluation of methylation profiles of an epidermal growth factor receptor gene in a head and neck squamous cell carcinoma patient group
Mutlu, M.; Mutlu, Pelin; Azarkan, S.; Baylr, Ö.; Öcal, B.; Saylam, G.; KORKMAZ, MEHMET HAKAN (2021-03-23)
Upregulation of the epidermal growth factor receptor (EGFR) gene has shown an important impact on the development of head and neck cancers due to its important regulation role on multiple cell signaling pathways. The aim of this study was to investigate the methylation pattern of the promoter region of the EGFR gene between head and neck squamous cell carcinoma (HNSCC) patients and a control group. Forty-seven unrelated HNSCC patients, clinically diagnosed at the Department of Otorhinolaryngology, Dlşkapl Y...
Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
Gungor, Bilgi; Yagci, Fuat Cem; GÜRSEL, İHSAN; Gürsel, Mayda (2014-07-01)
Type I interferon inducers may potentially be engineered to function as antiviral and anticancer agents, or alternatively, vaccine adjuvants, all of which may have clinical applications. We recently described a simple strategy to convert a Toll-like receptor 9 (TLR9) agonist devoid of interferon alpha (IFN alpha) stimulating activity into a robust Type I interferon inducer with potent vaccine adjuvant activity.
Assessing the readiness of Turkish health information systems for integrating genetic/genomic patient data: System architecture and available terminologies, legislative, and protection of personal data.
Şık, Ayhan Serkan; Aydınoğlu, Arsev Umur; Aydın Son, Yeşim (Elsevier BV, 2020-12-08)
Advances in genetic/genomic research and translational studies drive the progress on molecular diagnosis, personalised treatment, and monitoring. Healthcare professionals and governments are encouraged to set administrative regulations and implement structured and interoperable representation to utilise the genetic/genomic data, which will support precision medicine approaches through Health Information Systems (HIS). Clear regulations and careful legislation are also crucial for the security and privacy of...
Citation Formats
J. H. Kim et al., “Operation Warp Speed: implications for global vaccine security,” LANCET GLOBAL HEALTH, pp. 0–0, 2021, Accessed: 00, 2021. [Online]. Available: https://hdl.handle.net/11511/91569.